Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4195 USD | +2.33% | +1.04% | -2.46% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.19M |
---|---|---|---|---|---|
Net income 2024 * | -28M | Net income 2025 * | -34M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.52
x | P/E ratio 2025 * |
-0.55
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.12% |
Latest transcript on Theriva Biologics, Inc.
1 day | +2.33% | ||
1 week | +1.04% | ||
Current month | -10.55% | ||
1 month | -8.47% | ||
3 months | -3.45% | ||
6 months | -6.78% | ||
Current year | -2.46% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 15-05-31 | |
Michael Kaleko
CTO | Chief Tech/Sci/R&D Officer | - | 12-02-29 |
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeff Wolf
BRD | Director/Board Member | 60 | 05-12-31 |
John Monahan
BRD | Director/Board Member | 77 | 20-11-10 |
Jeffrey Kraws
CHM | Chairman | 59 | 05-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.4195 | +2.33% | 169,126 |
24-04-25 | 0.41 | +11.22% | 312,064 |
24-04-24 | 0.3686 | -2.20% | 122,599 |
24-04-23 | 0.3769 | -8.30% | 1,193,488 |
24-04-22 | 0.411 | -1.01% | 1,155,132 |
Delayed Quote Nyse, April 26, 2024 at 04:10 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.46% | 7.19M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TOVX Stock